Trademark: 76463019
Word
ERBITUX CETUXIMAB
Status Date
Friday, October 10, 2014
Registration Number
3392234
Registration Date
Tuesday, March 4, 2008
Filing Date
Tuesday, September 10, 2002
Published for Opposition
Tuesday, April 29, 2003
Cancellation Date
Friday, October 10, 2014
5 PHARMACEUTICAL PREPARATION, NAMELY, MONOCLONAL ANTIBODY FOR THE TREATMENT OF CANCER
Color is not claimed as a feature of the mark.
"CETUXIMAB"
The mark comprises the words ERBITUX CETUXIMAB and an antibody design (shown in stippling).
The stippling is for shading purposes.
Oct 10, 2014
Cancelled Sec. 8 (6-Yr)
Jun 3, 2009
Attorney Revoked And/Or Appointed
Jun 3, 2009
Teas Revoke/Appoint Attorney Received
Feb 4, 2009
Assignment Of Ownership Not Updated Automatically
Mar 21, 2008
Teas Change Of Correspondence Received
Mar 4, 2008
Registered-Principal Register
Jan 28, 2008
Law Office Registration Review Completed
Jan 25, 2008
Allowed Principal Register - Sou Accepted
Jan 25, 2008
Examiners Amendment Mailed
Jan 24, 2008
Examiner's Amendment Entered
Jan 24, 2008
Su-Examiner's Amendment Written
Dec 26, 2007
Examiners Amendment Mailed
Dec 22, 2007
Examiner's Amendment Entered
Dec 21, 2007
Su-Examiner's Amendment Written
Dec 18, 2007
Non-Final Action Mailed
Dec 17, 2007
Su - Non-Final Action - Written
Oct 31, 2007
Amendment From Applicant Entered
Oct 31, 2007
Correspondence Received In Law Office
Oct 31, 2007
Assigned To Lie
Sep 25, 2007
Paper Received
Sep 5, 2007
Non-Final Action Mailed
Sep 4, 2007
Su - Non-Final Action - Written
Aug 10, 2007
Statement Of Use Processing Complete
Jun 8, 2007
Use Amendment Filed
Jun 8, 2007
Paper Received
Jun 5, 2007
Assigned To Examiner
Apr 10, 2007
Noa Mailed - Sou Required From Applicant
Feb 20, 2007
Opposition Terminated No. 999999
Nov 29, 2006
Paper Received
Nov 6, 2003
Opposition Instituted No. 999999
Apr 29, 2003
Published For Opposition
Apr 9, 2003
Notice Of Publication
Feb 21, 2003
Approved For Pub - Principal Register
Feb 21, 2003
Assigned To Examiner
Trademark Alertz updated from USPTO on 2030-01-24
